Research and development innovation resonate with business transformation, revealing new trends in the development of innovative pharmaceutical companies.

Recently, Hengrui Pharmaceuticals held a performance briefing for the third quarter of 2025. Feng Ji, director, president, and chief operating officer of Hengrui Pharmaceuticals, stated at the performance briefing that the Chinese market for innovative drugs is entering a period of rapid development, and the company, as a leading domestic enterprise, will continue to benefit from policy support and industry expansion opportunities. At the same time, in recent times, several innovative drug companies like Dizhi Pharmaceuticals and Zhejing Pharmaceuticals have successively held performance briefings for the third quarter. The research and development progress of innovative drug pipelines, technology investment, and industry development prospects have become the focus of investors. Industry insiders state that with the acceleration of commercialization and BD transactions in the domestic innovative drug industry, the rapid growth trend of the innovative drug industry's performance is expected to continue.